Description: Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases in the United States. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. The company also completed preclinical proof-of-concept studies, and Phase I and Phase II clinical trials of a treatment for alpha-1 antitrypsin deficiency, an inherited orphan lung disease. In addition, it has proof-of-concept programs for other eye diseases, such as leber congenital amaurosis (type 2), and wet form of age-related macular degeneration. Applied Genetic Technologies Corporation was founded in 1999 and is headquartered in Alachua, Florida.
Home Page: agtc.com
AGTC Technical Analysis
14193 NW 119th Terrace
Alachua,
FL
32615
United States
Phone:
386 462 2204
Officers
| Name | Title |
|---|---|
| Ms. Susan B. Washer | Pres, CEO & Director |
| Mr. Jonathan I. Lieber M.B.A. | Chief Financial Officer |
| Dr. Susan Schneider M.D. | Chief Medical Officer |
| Dr. Nicholas Muzyczka | Co-Founder |
| Dr. Barry J. Byrne M.D., Ph.D. | Co-Founder |
| Dr. William W. Hauswirth | Co-Founder & Member of Ophthalmology Scientific Advisory Board |
| Dr. Richard Jude Samulski Ph.D. | Co-Founder |
| Dr. Terence R. Flotte M.D. | Co-Founder |
| Mr. Gerald Anthony Reynolds | Chief Accounting Officer, Principal Accounting Officer & Treasurer |
| Dr. Abraham Scaria Ph.D. | Chief Scientific Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.5086 |
| Price-to-Sales TTM: | 81.9078 |
| IPO Date: | 2014-03-27 |
| Fiscal Year End: | June |
| Full Time Employees: | 102 |